Endo International PLC Stock Research

ENDP Stock Price

ENDP RSI Chart

ENDP Valuation

Market Cap

94.1M

Price/Earnings (Trailing)

-0.03

Price/Sales (Trailing)

0.04

EV/EBITDA

-3.06

Price/Free Cashflow

6.09

ENDP Price/Sales (Trailing)

ENDP Profitability

Operating Margin

52.89%

EBT Margin

-124.55%

Return on Assets

-50.77%

Free Cashflow Yield

16.42%

ENDP Fundamentals

ENDP Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

-21%

Revenue Q/Q

-7.29%

ENDP Earnings

Earnings (TTM)

-2.9B

Earnings Y/Y

95.44%

Earnings Q/Q

98.65%

Price Action

Last 7 days

-27.9%

Last 30 days

-44.0%

Last 90 days

-37.7%

Trailing 12 Months

-88.4%

ENDP Financial Health

Current Ratio

3.01

Debt/Cashflow

0.03

ENDP Investor Care

Shares Dilution (1Y)

0.05%

Diluted EPS (TTM)

-12.13

Peers (Alternatives to Endo International)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	402.2B	96.3B	-5.70%	-13.01%	31.61	4.18	1.46%	-35.83%
LLY	384.9B	27.7B	7.93%	32.88%	67.69	13.9	-5.56%	-7.22%
MRK	272.8B	57.9B	-5.46%	20.82%	17.88	4.63	7.21%	-8.11%
PFE	230.9B	93.0B	-4.83%	-30.22%	7.36	2.3	0.56%	16.36%
BMY	150.1B	45.8B	-4.58%	-15.10%	23.72	3.25	-2.37%	16.96%
MID-CAP
PRGO	5.0B	4.6B	-15.03%	-21.13%	-35.25	1.11	8.46%	-29.07%
RETA	3.5B	1.5M	-9.27%	202.73%	-11.32	1.6K	-86.94%	-16.59%
SMALL-CAP
SUPN	1.8B	668.5M	-9.77%	17.11%	34.67	2.7	11.17%	-29.04%
TLRY	1.6B	596.3M	-7.75%	-62.41%	-0.89	2.66	-3.41%	-3791.67%
INVA	853.7M	271.5M	10.57%	-16.11%	3.88	3.14	-31.50%	-40.28%
CRON	666.4M	112.3M	-6.42%	-42.62%	-4.29	5.94	7.69%	41.96%
ACRS	550.4M	30.8M	-7.87%	-37.00%	-5.72	17.86	378.90%	-19.01%
OCUL	495.3M	51.7M	3.06%	100.31%	-5.58	9.58	4.69%	-299.77%
CGC	413.3M	478.9M	-34.59%	-82.58%	-0.13	0.86	-31.50%	-634.70%
ENDP	94.1M	2.2B	-43.99%	-88.43%	-0.03	0.04	-25.47%	-292.77%

Financials for Endo International

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-5.9%	2,181,883,000	2,318,875,000	2,552,492,000	2,782,830,000	2,927,546,000
S&GA Expenses	-9.8%	700,801,000	777,169,000	850,315,000	904,958,000	901,747,000
EBITDA	6.4%	-2,146,697,000	-2,294,032,000	-1,549,338,000	346,388,000	-
EBITDA Margin	-3.0%	-0.93	-0.90	-0.56	0.12	-
Earnings Before Taxes	2.4%	-2,818,037,000	-2,888,102,000	-3,196,000,000	-2,536,149,000	-661,501,000
EBT Margin	0.5%	-1.25	-1.25	-0.91	-0.23	-
Interest Expenses	-38.6%	214,936,000	349,776,000	492,987,000	561,192,000	562,961,000
Net Income	2.4%	-2,854,410,000	-2,923,105,000	-3,241,632,000	-2,596,670,000	-726,743,000
Net Income Margin	0.7%	-1.26	-1.27	-0.93	-0.25	-
Free Cahsflow	997.0%	169,471,000	15,449,000	-4,006,000	284,308,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-3.3%	5,566	5,758	6,006	6,362	8,447
Current Assets	-7.0%	1,932	2,077	2,054	2,200	2,493
Cash Equivalents	12.4%	1,146	1,019	1,054	1,190	1,413
Inventory	3.9%	285	274	289	288	284
Goodwill	0%	1,352	1,352	1,352	1,449	3,197
Current Liabilities	-12.0%	607	690	543	1,182	1,376
Long Term Debt	-1.1%	7,979	8,065	8,067	-	-
LT Debt, Current	NaN%	-	-	26.00	26.00	-
LT Debt, Non Current	NaN%	-	-	8,039	8,041	-
Retained Earnings	0.0%	-12,907	-12,904	-12,661	-11,938	-10,053
Additional Paid-In Capital	0.1%	8,981	8,969	8,966	8,960	8,957
Shares Outstanding	0.0%	235	235	235	235	235

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-51.7%	130	269	110	80.00	369
Share Based Compensation	36.5%	24.00	17.00	21.00	23.00	25.00
Cashflow From Investing	20.6%	-105	-133	-123	-126	-91.34
Cashflow From Financing	8.7%	-469	-513	-397	-236	-247

Risks for ENDP

What is the probability of a big loss on ENDP?

100%

Probability that Endo International stock will be more than 20% underwater in next one year

100%

Probability that Endo International stock will be more than 30% underwater in next one year.

90.4%

Probability that Endo International stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ENDP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Endo International was unfortunately bought at previous high price.

Drawdowns

Returns for ENDP

Cumulative Returns on ENDP

-37.6%

10-Year Cumulative Returns

-55.1%

7-Year Cumulative Returns

-49.6%

5-Year Cumulative Returns

-53.5%

3-Year Cumulative Returns

What are the long-term rolling returns for ENDP?

FIve years rolling returns for Endo International.

Annualized Returns

Which funds bought or sold ENDP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-15	MEEDER ASSET MANAGEMENT INC	unchanged	-	-2.00	132	-%
2023-05-02	HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC	added	8.33	-	-	-%
2022-07-19	Lake Point Wealth Management	sold off	-100	-2,000	-	-%
2022-05-16	Amalgamated Financial Corp.	new	-	239,000	239,000	-%
2022-05-16	Parametric Portfolio Associates LLC	reduced	-48.7	-2,245,000	1,033,000	-%
2022-04-27	ADVISOR PARTNERS LLC	sold off	-100	-139,000	-	-%
2022-04-21	FIRST QUADRANT LLC/CA	new	-	36,000	36,000	0.20%
2022-04-07	Fieldpoint Private Securities, LLC	sold off	-100	-3,000	-	-%
2022-02-15	NEXT Financial Group, Inc	unchanged	-	1,000	9,000	-%
2021-10-07	Berman Capital Advisors, LLC	sold off	-100	-1,000	-	-%

Latest Funds Activity

Are funds buying ENDP calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ENDP

No. of Funds

Endo International News

Schedule 13G FIlings of Endo International

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	renaissance technologies llc	0.00%	0	SC 13G/A
Sep 08, 2022	blackrock inc.	0.7%	1,556,382	SC 13G
Aug 29, 2022	millennium management llc	2.0%	4,595,233	SC 13G
Jul 08, 2022	blackrock inc.	7.9%	18,633,065	SC 13G
Feb 14, 2022	paulson & co. inc.	7.4%	-	SC 13G
Feb 11, 2022	renaissance technologies llc	6.47%	15,109,161	SC 13G/A
Jan 27, 2022	blackrock inc.	15.8%	36,827,860	SC 13G/A
Jan 26, 2022	blackrock inc.	15.8%	36,827,860	SC 13G/A
Feb 16, 2021	glenview capital management, llc	3.25%	7,489,768	SC 13G/A
Feb 16, 2021	miller value partners, llc	0.13%	294,150	SC 13G/A

ENDP Fair Value

Show Fair-Value

Recent SEC filings of Endo International

View All Filings

Date Filed	Form Type	Document
May 30, 2023	8-K	Current Report
May 08, 2023	8-K	Current Report
May 08, 2023	10-Q	Quarterly Report
Apr 28, 2023	10-K/A	Annual Report
Mar 31, 2023	8-K	Current Report
Mar 06, 2023	8-K	Current Report
Mar 06, 2023	8-K	Current Report
Mar 06, 2023	10-K	Annual Report
Feb 27, 2023	S-8 POS	Employee Benefits Plan
Feb 27, 2023	S-8 POS	Employee Benefits Plan

Latest Insider Trading transactions for ENDP

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-07-15	Tursi James Patrick	back to issuer	-	-	-280,373	executive vp, global r&d
2022-03-30	Bradley Mark T.	acquired	-	-	10,735	evp, chief financial officer
2022-03-30	Barry Patrick A	sold (taxes)	-12,537	2.52	-4,975	evp & pres,global comm ops
2022-03-30	Maletta Matthew Joseph	sold (taxes)	-25,651	2.52	-10,179	evp, clo & company secretary
2022-03-30	Maletta Matthew Joseph	sold	-	-	-85,927	evp, clo & company secretary
2022-03-30	Bradley Mark T.	sold	-	-	-26,805	evp, chief financial officer
2022-03-30	Maletta Matthew Joseph	acquired	-	-	34,414	evp, clo & company secretary
2022-03-30	Coleman Blaise	sold (taxes)	-25,545	2.52	-10,137	president, ceo
2022-03-30	Coleman Blaise	sold	-	-	-89,663	president, ceo
2022-03-30	Bradley Mark T.	sold (taxes)	-7,703	2.52	-3,057	evp, chief financial officer

About Endo International

Blaise A. Coleman

www.endo.com

3100

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

ENDP Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
TOTAL REVENUES, NET	$ 515,267	$ 652,259
COSTS AND EXPENSES:
Cost of revenues	232,742	273,215
Selling, general and administrative	150,793	227,161
Research and development	27,703	36,130
Acquired in-process research and development	0	2,900
Litigation-related and other contingencies, net	15,200	25,154
Asset impairment charges	146	19,953
Acquisition-related and integration items, net	397	(1,377)
Interest expense, net	109	134,949
Reorganization items, net	85,352	0
Other (income) expense, net	(125)	1,289
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAX	2,950	(67,115)
INCOME TAX EXPENSE (BENEFIT)	5,773	(1,815)
LOSS FROM CONTINUING OPERATIONS	(2,823)	(65,300)
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 4)	(456)	(6,674)
Net loss	$ (3,279)	$ (71,974)
NET (LOSS) INCOME PER SHARE—BASIC:
Continuing operations (in dollars per share)	$ (0.01)	$ (0.28)
Discontinued operations (in dollars per share)	0	(0.03)
Basic (in dollars per share)	(0.01)	(0.31)
NET (LOSS) INCOME PER SHARE—DILUTED:
Continuing operations (in dollars per share)	(0.01)	(0.28)
Discontinued operations (in dollars per share)	0	(0.03)
Diluted (in dollars per share)	$ (0.01)	$ (0.31)
WEIGHTED AVERAGE SHARES:
Basic (in shares)	235,216	233,879
Diluted (in shares)	235,216	233,879

ENDP Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 903,613	$ 1,018,883
Restricted cash and cash equivalents	157,039	145,358
Accounts receivable, net	459,355	493,988
Inventories, net	285,284	274,499
Prepaid expenses and other current assets	120,906	136,923
Income taxes receivable	5,559	7,117
Total current assets	1,931,756	2,076,768
PROPERTY, PLANT AND EQUIPMENT, NET	460,104	438,314
OPERATING LEASE ASSETS	26,871	28,070
GOODWILL	1,352,011	1,352,011
OTHER INTANGIBLES, NET	1,667,809	1,732,935
DEFERRED INCOME TAXES	8	0
OTHER ASSETS	127,546	129,839
TOTAL ASSETS	5,566,105	5,757,937
CURRENT LIABILITIES:
Accounts payable and accrued expenses	603,933	687,183
Current portion of operating lease liabilities	869	903
Income taxes payable	1,841	1,541
Total current liabilities	606,643	689,627
DEFERRED INCOME TAXES	12,160	13,825
OPERATING LEASE LIABILITIES, LESS CURRENT PORTION	4,940	5,129
OTHER LIABILITIES	55,221	42,746
LIABILITIES SUBJECT TO COMPROMISE	9,040,746	9,168,782
COMMITMENTS AND CONTINGENCIES (NOTE 15)
SHAREHOLDERS’ DEFICIT:
Euro deferred shares, $0.01 par value; 4,000,000 shares authorized and issued at both March 31, 2023 and December 31, 2022	43	43
Ordinary shares, $0.0001 par value; 1,000,000,000 shares authorized; 235,219,612 and 235,208,039 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	24	24
Additional paid-in capital	8,980,561	8,969,322
Accumulated deficit	(12,907,899)	(12,904,620)
Accumulated other comprehensive loss	(226,334)	(226,941)
Total shareholders’ deficit	(4,153,605)	(4,162,172)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$ 5,566,105	$ 5,757,937